Ondansetron Injection Rx
Generic Name and Formulations:
Ondansetron (as HCl dihydrate) 2mg/mL; IV or IM inj.
Various generic manufacturers
Indications for Ondansetron Injection:
Prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including high-dose cisplatin. Prevention of post-op nausea and vomiting.
Chemotherapy (vials must be diluted; see full labeling): >18yrs: Infuse over 15 mins. 0.15mg/kg (max 16mg/dose) IV every 4hrs for 3 doses beginning 30 mins before chemotherapy. Severe hepatic dysfunction: max 8mg/day. Post-op (do not dilute): Infuse in not less than 30 seconds, preferably over 2–5 mins: 4mg IV as single dose immediately before induction of anesthesia; or shortly post-op if nausea or vomiting occurs. Or, may use 4mg IM undiluted as a single injection.
Chemotherapy (vials must be diluted; see full labeling): Infuse over 15 mins. <6 months: see full labeling. 6 months–18yrs: 0.15mg/kg (max 16mg/dose) IV for 3 doses every 4hrs beginning 30 mins before chemotherapy. Post-op (do not dilute): Infuse in not less than 30 seconds, preferably over 2–5 mins: <1 month: see full labeling. 1 month–12yrs (<40kg): 0.1mg/kg. ≥40kg: 4mg. Give IV as single dose immediately before induction of anesthesia; or shortly post-op if nausea or vomiting occurs.
<4 months of age (monitor closely). Not a substitute for nasogastric suction in gastric or intestinal peristalsis. Congenital long QT syndrome: avoid. Electrolyte abnormalities, CHF, bradyarrhythmias, concomitant drugs that prolong QT: monitor ECG. May mask progressive ileus and/or gastric distention. GI obstruction risk: monitor for decreased bowel activity. Hepatic dysfunction. Pregnancy. Nursing mothers.
See Contraindications. Profound hypotension, loss of consciousness with apomorphine. Serotonin syndrome possible esp. with concomitant serotonergic drugs (eg, SSRIs, SNRIs, MAOIs, mirtazapine, fentanyl, lithium, tramadol, IV methylene blue). May antagonize tramadol.
Selective 5-HT3 receptor antagonist.
Diarrhea, headache, fever, constipation, fatigue, transient blindness; serotonin syndrome (discontinue if occurs); rare: angina, bronchospasm, anaphylaxis, seizures, ECG changes (including QT prolongation).
Tabs 4mg, 8mg—30; ODT 4mg, 8mg—30; Oral soln, vials—contact supplier
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Nicotinamide and Cancer
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- Opioid Prescription Protocol Decreases Opioid Use After Gynecologic Surgery
- Everolimus Plus Letrozole May Be Active in Recurrent Endometrial Carcinoma
- Affordable Care Act Increased Percentage of Insured Patients With Gynecologic Cancers
- Everolimus Plus Letrozole: An Effective First-Line Therapy for Advanced Breast Cancer
- FDA Approves Nilotinib for Pediatric Patients With CML